Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Roivant's reported figures suggest a company still in a heavy investment phase, with quarterly operating losses ranging from roughly -$102M to -$366M and revenue only $1.4M to $35.1M in recent quarters, leaving gross profit far too small to absorb R&D and SG&A that run near $145M to $203M each per quarter.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has been lumpy, reaching $35.1M in 2026Q2 after $1.4M in 2026Q1, yet operating margin remained deeply negative at -7.6% in the latest quarter and -253.8% the prior quarter, indicating fixed operating costs still overwhelm gross profit.
Roivant Sciences is expanding its brepocitinib development program with a new Phase 2b/3 trial in Lichen Planopilaris (LPP), indicating potential growth in its pipeline.
The U.S. FDA has accepted Roivant's New Drug Application for brepocitinib in dermatomyositis and granted Priority Review, targeting a potential launch by Q3 2026.
Positive Phase 3 study results for batoclimab in Thyroid Eye Disease (TED) could drive investor confidence and future revenue streams.
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 9, 2026 | -$0.27+26.4% vs -$0.37 | $35M+710.0% vs $4M |
Q3 2026 Aug 6, 2026 | -$0.33-10.1% vs -$0.30 | $1M-29.9% vs $2M |
Q2 2026 May 20, 2026 | -$0.28+3.5% vs -$0.29 | $3M-26.2% vs $3M |
Q1 2026 Feb 6, 2026 | -$0.24+19.9% vs -$0.30 | $2M-60.6% vs $5M |
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in rheumatoid arthritis, but regulatory and translational hurdles remain for broader adoption. Priovant's LISRAYA launches in dermatomyositis, with promising Phase 3 data in non-infectious uveitis, while Pulmovant's mosliciguat demonstrates best-in-class Phase 2 results in PH-ILD.

DURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib in adults with cutaneous sarcoidosis (CS). The publication describes improvements in skin disease activity and skin-related quality of life over 16 weeks of treatment, with 69.2% of participants receiving brepocitinib 45 mg once daily achieving “Clear” or “Almost Clear” skin with at least a 2-category improvement, compared with none of the participants receiving placebo (P = 0.0047).

CenterBook Partners LP decreased its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 35.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,188 shares of the company's stock after selling 18,928 shares during the period. CenterBook Partners LP's holdings in
Benchmark ROIV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Roivant Sciences Ltd. (ROIV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $38.71 | $27.96B | -81.26 | -71.57% | -838.19% | -6.96% | — | |
| $13.24 | $1.99B | -3.69 | — | — | -2271.87% | — | |
| $33.21 | $6.85B | -13.49 | — | -7173.52% | -63.01% | — | |
| $121.52 | $10B | -34.81 | -16.72% | -341.87% | -22.39% | — | |
| $305.06 | $8.5B | -24.77 | -100% | — | -29.41% | — | |
| $292.86 | $517.42B | 50.14 | 8.57% | 15.68% | — | 2.24% |
Roivant Sciences Ltd. (ROIV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Roivant Sciences Ltd. (ROIV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 9, 2026·SEC
Oct 21, 2026·SEC
Aug 6, 2026·SEC
Get notified when ROIV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Roivant Sciences Ltd. (ROIV) stock FAQ — growth, dividends, profitability & financials explained
Roivant Sciences Ltd. (ROIV) reported $41.1M in revenue over the trailing twelve months. Revenue was $8.3M in fiscal year 2025. That is 88% less than the $67.7M of fiscal year 2019.
Roivant Sciences Ltd. (ROIV) grew revenue by 102.1% over the trailing twelve months, compared with the twelve months before.
No. Roivant Sciences Ltd. (ROIV) reported a net loss of $344.3M over the trailing twelve months.
Roivant Sciences Ltd. (ROIV) had a return on equity (ROE) of -7.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Roivant Sciences Ltd. (ROIV) had negative free cash flow of $26.2M over the trailing twelve months.